CLINICAL-TRIAL OF CEFOTAXIME IN PATIENTS WITH TYPHOID-FEVER

  • 1 January 1985
    • journal article
    • research article
    • Vol. 7  (4) , 448-451
Abstract
In 45 patients in whom typhoid fever was confirmed by culture of a blood sample, cefotaxime (1 g BID [twice a day]) was administered i.v. for 4 days; if defervescence did not occur by day 5, the dosage was increased to 2 g BID until defervescence, when it was reduced to 1 g BID until discharge. On average, defervescence occurred on day 7 (range, day 3-14), requiring a total dose of 31 g (range, 12-60 g) of cefotaxime. Relapse, occurring in 3 patients, was treated with co-trimoxazole. The duration of cefotaxime therapy was longer than therapy with chloramphenicol but without the risk of bone marrow depression.